# CM Life Sciences III

CM Life Sciences III is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** 667 Madison Ave, New York, NY 10065, United States
- **Assets under management:** Undisclosed
- **Website:** iii.cmlifesciencesspac.com

## Regulatory record

- **Reports private funds:** No

## About

CM Life Sciences III is a NASDAQ-listed Special Purpose Acquisition Company (SPAC) formed to pursue a business combination with one or more entities. It is listed under the ticker symbol CMLT.

## Sectors

- Life Sciences
- Healthcare Services
- Biotech

## Offices

- Menlo Park
- Abu Dhabi
- Baltimore
- Dallas
- San Francisco

## People

- Eli Casdin — CEO
- Keith Meister — Board of Directors

## Questions

### Who manages investment decisions at CM Life Sciences III?

Eli Casdin, founder and CIO of Casdin Capital, serves as CEO of CM Life Sciences III and leads the investment platform. Keith Meister, founder of Corvex Management, provides capital markets and board expertise. The SPAC's board includes independent directors with life sciences industry and operational experience.

### What investment stages does CM Life Sciences III target?

CM Life Sciences III focuses on private companies in the life sciences ecosystem that are under-resourced and under-scaled but have defensible IP and long product life cycles. The SPAC is designed to provide public currency for buy-and-build strategies, targeting firms that find it hard to access public capital markets but need to scale.

### Which sectors does CM Life Sciences III explicitly invest in?

The firm targets services and tools supporting drug discovery, development, and manufacturing; molecular diagnostics; synthetic biology; and regulated products for R&D across academia, government, and industry. It also seeks companies with regulated products that have long and lucrative life cycles, as well as those exploiting technological advances in engineering of biological systems.

### What is CM Life Sciences III's relationship to Casdin Capital?

CM Life Sciences III is formed by Eli Casdin, founder of Casdin Capital, a $3.3B life sciences investment firm. The SPAC draws on Casdin Capital's deep sector expertise, proprietary deal flow, and reputation as a leading investor in both public and private life sciences markets. Casdin Capital's investment team supports the SPAC's sourcing and due diligence.

### What is CM Life Sciences III's known posture on co-investments alongside external GPs?

The SPAC is structured as a standalone entity that raises capital through its IPO and then combines with target companies. It does not appear to operate as a co-investment vehicle alongside external GPs. Its strategy is to use its own public currency to execute buy-and-build consolidation in the life sciences sector.

## Related profiles

- [The InterMed Group](https://altss.com/profile/the-intermed-group)
- [Sorrento Therapeutics](https://altss.com/profile/sorrento-therapeutics)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cm-life-sciences-iii

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology